表紙:XP-3924の新興薬剤に関する洞察と市場予測:2032年
市場調査レポート
商品コード
1381094

XP-3924の新興薬剤に関する洞察と市場予測:2032年

XP-3924 Emerging Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.66円
XP-3924の新興薬剤に関する洞察と市場予測:2032年
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

XP-3924は、2つの補完的治療薬であるプラムリンタイド(アミリン類似物質)とインスリンの相乗的な組み合わせを改善します。これらの既存療法を別々に併用投与することで、食後血糖上昇と血糖変動の両方を抑制し、全体的な血糖コントロールを改善します。

今後数年間で、1型糖尿病の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、XP-3924の優位性に影響を与える可能性のある機会を模索しています。1型糖尿病に対する他の新興製品がXP-3924に厳しい市場競合を与えることが予想され、近い将来に後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるXP-3924市場について調査し、市場の概要とともに、2027年~2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 1型糖尿病に対するXP-3924の概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • その他の開発活動
  • 製品概要

第3章 競合情勢(上市済み治療法)

第4章 競合情勢(後期段階の新興治療法)

第5章 XP-3924市場評価

  • 1型糖尿病に対するXP-3924の市場展望
  • 主要7ヶ国市場分析
    • 主要7ヶ国における1型糖尿病に対するXP-3924の市場規模
  • 国別市場分析
    • 米国
    • ドイツ
    • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: XP-3924, Clinical Trial Description, 2023
  • Table 2: XP-3924, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: XP-3924 Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: XP-3924 Market Size in the US, in USD million (2019-2032)
  • Table 7: XP-3924 Market Size in Germany, in USD million (2019-2032)
  • Table 8: XP-3924 Market Size in France, in USD million (2019-2032)
  • Table 9: XP-3924 Market Size in Italy, in USD million (2019-2032)
  • Table 10: XP-3924 Market Size in Spain, in USD million (2019-2032)
  • Table 11: XP-3924 Market Size in the UK, in USD million (2019-2032)
  • Table 12: XP-3924 Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: XP-3924 Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: XP-3924 Market Size in the United States, USD million (2019-2032)
  • Figure 3: XP-3924 Market Size in Germany, USD million (2019-2032)
  • Figure 4: XP-3924 Market Size in France, USD million (2019-2032)
  • Figure 5: XP-3924 Market Size in Italy, USD million (2019-2032)
  • Figure 6: XP-3924 Market Size in Spain, USD million (2019-2032)
  • Figure 7: XP-3924 Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: XP-3924 Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1040

“"XP-3924 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XP-3924 for type 1 diabetes mellitus in the seven major markets. A detailed picture of the XP-3924 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XP-3924 for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XP-3924 market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

XP-3924 improves the synergistic combination of two complementary therapies - pramlintide (an amylin-analog) and insulin. The separate administration of these existing therapies in combination reduces both postprandial glucose excursions and glucose variability and improves overall glycemic control.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the XP-3924 description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
  • Elaborated details on XP-3924 regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the XP-3924 research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around XP-3924.
  • The report contains forecasted sales of XP-3924 for type 1 diabetes mellitus till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
  • The report also features the SWOT analysis with analyst views for XP-3924 in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XP-3924 Analytical Perspective by DelveInsight

In-depth XP-3924 Market Assessment

This report provides a detailed market assessment of XP-3924 for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

XP-3924 Clinical Assessment

The report provides the clinical trials information of XP-3924 for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XP-3924 dominance.
  • Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to XP-3924 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XP-3924 in type 1 diabetes mellitus.
  • Our in-depth analysis of the forecasted sales data of XP-3924 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XP-3924 in type 1 diabetes mellitus.

Key Questions:

  • What is the product type, route of administration and mechanism of action of XP-3924?
  • What is the clinical trial status of the study related to XP-3924 in type 1 diabetes mellitus and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XP-3924 development?
  • What are the key designations that have been granted to XP-3924 for type 1 diabetes mellitus?
  • What is the forecasted market scenario of XP-3924 for type 1 diabetes mellitus?
  • What are the forecasted sales of XP-3924 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to XP-3924 for type 1 diabetes mellitus?
  • Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. XP-3924 Overview in type 1 diabetes mellitus

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. XP-3924 Market Assessment

  • 5.1. Market Outlook of XP-3924 in type 1 diabetes mellitus
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of XP-3924 in the 7MM for type 1 diabetes mellitus
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of XP-3924 in the United States for type 1 diabetes mellitus
    • 5.3.2. Market Size of XP-3924 in Germany for type 1 diabetes mellitus
    • 5.3.3. Market Size of XP-3924 in France for type 1 diabetes mellitus
    • 5.3.4. Market Size of XP-3924 in Italy for type 1 diabetes mellitus
    • 5.3.5. Market Size of XP-3924 in Spain for type 1 diabetes mellitus
    • 5.3.6. Market Size of XP-3924 in the United Kingdom for type 1 diabetes mellitus
    • 5.3.7. Market Size of XP-3924 in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options